Macrogenics (MGNX) Depreciation & Amortization (CF) (2012 - 2026)
Macrogenics' (MGNX) quarterly Depreciation & Amortization (CF) came in at $1.7 million in Q1 2026, down 4.74% year-on-year from $1.8 million in Q1 2025, and down 1.06% on a QoQ basis from $1.7 million in Q4 2025.
Macrogenics (MGNX) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Depreciation & Amortization (CF) data on file, last reported at $1.7 million in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 4.74% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 5.11% decrease from a year earlier, with the FY2025 full-year figure at $7.2 million, down 4.88% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $1.7 million, down from $1.7 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for MGNX reached as high as $3.2 million in Q4 2022 and fell as low as $1.7 million in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $2.2 million across 5 years, with a median of $1.9 million in 2025.
- Across the five-year window, Depreciation & Amortization (CF) advanced 9.45% in 2022 and slumped 41.19% in 2023, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $3.2 million in 2022, then tumbled by 41.19% to $1.9 million in 2023, then climbed by 8.05% to $2.1 million in 2024, then decreased by 16.95% to $1.7 million in 2025, then declined by 1.06% to $1.7 million in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Macrogenics | 254.43 Mn | 187.92 Mn | - | 1.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.69 Mn |
| Mar 31, 2026 | 1.69 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | 1.84 Mn |
| Mar 31, 2024 | 1.84 Mn |
| Dec 31, 2023 | 1.90 Mn |
| Dec 31, 2023 | 1.90 Mn |